What is the price target for IONS stock?
29 analysts have analysed IONS and the average price target is 97.41 USD. This implies a price increase of 29.58% is expected in the next year compared to the current price of 75.17.
IONIS PHARMACEUTICALS INC (IONS) Forecast, Price Target & Analyst Ratings
NASDAQ:IONS • US4622221004
Current stock price
75.17 USD
-1.26 (-1.65%)
At close:
75.17 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IONIS PHARMACEUTICALS INC (IONS).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 28, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.91
- Revenue Estimate
- 202.14M
Price Target Details & History
Consensus Price Target and Range
Mean target
$97.41
Upside
+ 29.58%
From current price of $75.17 to mean target of $97.41, Based on 29 analyst forecasts
Low
$46.46
Median
$102.00
High
$126.00
Price Target Revisions
1 Month
5.69%
3 Months
11.64%
Price Target Summary
29 Wall Street analysts provided a forecast for the next 12 months for IONS. The average price target is 97.41 USD. This implies a price increase of 29.58% is expected in the next year compared to the current price of 75.17.
The average price target has been revised upward by 11.64% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.38%
IONS was analyzed by 29 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about IONS.
In the previous month the buy percentage consensus was at a similar level.
IONS was analyzed by 29 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-09 | B of A Securities | Maintains | Buy -> Buy |
| 2026-03-26 | Barclays | Maintains | Overweight -> Overweight |
| 2026-03-25 | Needham | Maintains | Buy -> Buy |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-03 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-02-26 | Stifel | Maintains | Hold -> Hold |
| 2026-02-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-15 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-30 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-30 | Needham | Maintains | Buy -> Buy |
| 2025-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-30 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-30 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
| 2025-10-30 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-08 | Needham | Maintains | Buy -> Buy |
| 2025-10-08 | Oppenheimer | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 28, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.91
- Revenue Estimate
- 202.14M
- Revenue Q2Q
- 53.14%
- EPS Q2Q
- 2.61%
- Number of Analysts
- 19
Next Earnings Revisions
Revenue (1 Month)
-0.37%
Revenue (3 Months)
5.14%
EPS (1 Month)
-2.49%
EPS (3 Months)
-14.42%
Next Earnings Summary
IONS is expected to report earnings on 4/28/2026. The consensus EPS estimate for the next earnings is -0.91 USD and the consensus revenue estimate is 202.14M USD.
The next earnings revenue estimate has been revised upward by 5.14% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 787.647M 34.09% | 705.138M -10.48% | 943.711M 33.83% | 840.27M -10.96% | 1.487B 76.97% | 2.068B 39.07% | 2.745B 32.74% | 3.564B 29.84% | 4.3B 20.65% | 4.933B 14.72% | 5.292B 7.28% | |
| EBITDA YoY % growth | -320.879M 18.46% | -463.131M -44.33% | -369.237M 20.27% | -670.087M -81.48% | -176.909M 73.60% | -53.214M 69.92% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -333.73M 18.64% | -475.081M -42.35% | -381.684M 19.66% | -678.852M -77.86% | -298.641M 56.01% | 57.133M 119.13% | 748.65M 1,210.36% | 1.396B 86.47% | 1.892B 35.53% | 2.363B 24.89% | 2.621B 10.92% | |
| Operating Margin | -42.37% | -67.37% | -40.45% | -80.79% | -20.08% | 2.76% | 27.27% | 39.17% | 44.00% | 47.90% | 49.53% | |
| EPS YoY % growth | -2.56 11.42% | -3.04 -18.75% | -2.44 19.74% | -4.19 -71.66% | -1.36 67.47% | 0.98 172.27% | 4.04 310.02% | 6.47 60.37% | 8.56 32.18% | 9.99 16.72% | 10.93 9.39% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.91 2.61% | -1.11 -257.89% | -1.10 -37.24% | -1.03 27.17% | -1.12 -23.88% | -0.99 10.48% | -0.79 28.47% | -0.65 36.43% |
| Revenue Q2Q % growth | 202.14M 53.14% | 188.05M -58.40% | 202.15M 28.76% | 244.18M 20.29% | 222.61M 10.13% | 271.47M 44.36% | 340.31M 68.35% | 427.19M 74.95% |
| EBITDA Q2Q % growth | -138.113M 4.12% | -175.732M -220.79% | -200.02M -31.91% | -173.936M 13.90% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -152.254M -3.67% | -179.874M -228.65% | -183.103M -14.31% | -170.028M 20.72% | -95.099M 37.54% | -71.096M 60.47% | 9.155M 105.00% | 76.197M 144.81% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
33.95%
EPS Next 5 Year
36.01%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
31.20%
Revenue Next 5 Year
31.23%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
23.01%
EBIT Next 5 Year
N/A
IONIS PHARMACEUTICALS INC / IONS Forecast FAQ
When does IONIS PHARMACEUTICALS INC (IONS) report earnings?
IONIS PHARMACEUTICALS INC (IONS) will report earnings on 2026-04-28.
What are the consensus estimates for IONIS PHARMACEUTICALS INC (IONS) next earnings?
The consensus EPS estimate for the next earnings of IONIS PHARMACEUTICALS INC (IONS) is -0.91 USD and the consensus revenue estimate is 202.14M USD.
What is the consensus rating for IONS stock?
The consensus rating for IONIS PHARMACEUTICALS INC (IONS) is 81.3793 / 100 . This indicates that analysts generally have a positive outlook on the stock.